The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 17, 2024

Filed:

Nov. 04, 2020
Applicant:

Celgene Corporation, Summit, NJ (US);

Inventors:

Tonia Buchholz, Moss Beach, CA (US);

Jinhong Fan, San Mateo, CA (US);

Daniel W. Pierce, Belmont, CA (US);

Michael Pourdehnad, San Francisco, CA (US);

Tsun-Wen Yao, San Francisco, CA (US);

Assignee:

Celgene Corporation, Summit, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/454 (2006.01); A61K 31/047 (2006.01); A61K 31/4545 (2006.01); A61K 31/573 (2006.01); A61K 31/593 (2006.01); A61K 33/06 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/454 (2013.01); A61K 31/047 (2013.01); A61K 31/4545 (2013.01); A61K 31/573 (2013.01); A61K 31/593 (2013.01); A61K 33/06 (2013.01); A61K 38/2006 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01);
Abstract

Provided herein are methods of treating, preventing, managing, and/or ameliorating hypotension related to administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cancer patient, wherein the methods comprise administering a combination comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, or an interleukin-1β blocker.


Find Patent Forward Citations

Loading…